KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for LifeMD (LFMD) over the last 14 years, with Q3 2025 value amounting to $3.2 million.

  • LifeMD's Share-based Compensation rose 3357.24% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year decrease of 1431.9%. This contributed to the annual value of $12.2 million for FY2024, which is 203.81% down from last year.
  • Per LifeMD's latest filing, its Share-based Compensation stood at $3.2 million for Q3 2025, which was up 3357.24% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, LifeMD's Share-based Compensation ranged from a high of $4.5 million in Q1 2022 and a low of $1.8 million during Q4 2022
  • Its 5-year average for Share-based Compensation is $3.1 million, with a median of $3.1 million in 2024.
  • Data for LifeMD's Share-based Compensation shows a peak YoY increase of 232520.86% (in 2021) and a maximum YoY decrease of 8098.99% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows LifeMD's Share-based Compensation stood at $4.1 million in 2021, then plummeted by 55.12% to $1.8 million in 2022, then skyrocketed by 98.71% to $3.6 million in 2023, then fell by 14.83% to $3.1 million in 2024, then increased by 3.0% to $3.2 million in 2025.
  • Its Share-based Compensation stands at $3.2 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.5 million for Q1 2025.